Childhood Cancer

You are here

Inhibition of translation initiation as a novel therapeutic strategy against MYCN-amplified neuroblastoma

Institution: 
Dana-Farber Cancer Institute
Researcher(s): 
Rani George, MD, PhD
Grant Type: 
Innovation Grants
Year Awarded: 
2022
Type of Childhood Cancer: 
Neuroblastoma
Project Description: 

The goal of this project is to test a novel strategy for disrupting the effects of MYCN amplification, which is seen in over 50% of high risk neuroblastoma patients. Although the association of MYCN amplification with a poor outcome is well established, attempts to directly target MYCN have been challenging. Therefore, we propose to tackle one of the consequences of amplified MYCN that enables abnormal cell growth, that of increased protein expression (translation). Proteins are the “doers” in the cell and originate from RNA. MYCN amplified cells have increased levels of protein production. We plan to disrupt such protein synthesis in MYCN-amplified neuroblastoma using novel small molecule inhibitors of one of the first critical steps in converting RNA into protein - translation initiation. This new class of compounds specifically target eIF4A, a molecule that is critical for translation initiation. We have identified a candidate compound that kills MYCN-amplified neuroblastoma cells while sparing normal cells. In this application, we plan to ensure that such a strategy is clinically feasible by testing it in animal models of human neuroblastoma, and to study the mechanism by which this class of inhibitors selectively targets neuroblastoma cells with MYCN amplification. Our studies will provide preclinical validation of this novel group of compounds that can then be taken forward into clinical development.

Project Goals:

The goal of this project is to test a novel strategy for disrupting the effects of MYCN amplification, which is seen in over 50% of high risk neuroblastoma patients. Although the association of MYCN amplification with a poor outcome is well established, attempts to directly target MYCN have been challenging. Therefore, we propose to tackle one of the consequences of amplified MYCN that enables abnormal cell growth, that of increased protein expression (translation). Proteins are the “doers” in the cell and originate from RNA. MYCN amplified cells have increased levels of protein production. We plan to disrupt such protein synthesis in MYCN-amplified neuroblastoma using novel small molecule inhibitors of one of the first critical steps in converting RNA into protein - translation initiation. This new class of compounds specifically target eIF4A, a molecule that is critical for translation initiation. We have identified a candidate compound that kills MYCN-amplified neuroblastoma cells while sparing normal cells. In this application, we plan to ensure that such a strategy is clinically feasible by testing it in animal models of human neuroblastoma, and to study the mechanism by which this class of inhibitors selectively targets neuroblastoma cells with MYCN amplification. Our studies will provide preclinical validation of this novel group of compounds that can then be taken forward into clinical development.